Precisely targeting the interface between
innate and adaptive immunity.
 

Dr. Mashal is President & CEO of NKT Therapeutics.  Before joining NKT Therapeutics, Dr. Mashal was President of Alinea Pharmaceuticals.  Prior to that, he was a partner at Boston Millenia Partners, a venture capital firm where he focused on investment opportunities in life sciences. He served as a Director of EpiGenesis Pharmaceuticals, Novalar Pharmaceuticals, GlycoFi, Sapphire Therapeutics, CoApt Systems, Protein Forest, and Cardiomems.  He was previously a Program Executive with Vertex Pharmaceuticals, where he led cancer drug development strategy and oversaw pre-clinical/clinical development, marketing, regulatory, and business activities. He was also a member of the Joint Research Committee for the $800 million Vertex-Novartis collaboration. Prior to that, Dr. Mashal served as a consultant at McKinsey & Company, and a faculty member and Attending Physician at Dana-Farber Cancer Institute, Brigham & Women's Hospital, and Harvard Medical School. Dr. Mashal is a diplomate in both internal medicine and oncology.  Dr. Mashal is a graduate of Johns Hopkins University and received his M.D. from Johns Hopkins University School of Medicine.